Skip to content

Ultrasonic Treatment of Food Addiction

Noninvasive Targeted Neuromodulation for Treatment of Food Addiction

Status
Withdrawn
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06249711
Acronym
USFADD
Enrollment
0
Registered
2024-02-08
Start date
2024-03-03
Completion date
2024-03-03
Last updated
2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Brief summary

This study will evaluate a new form of non-invasive deep brain therapy for food addiction. Low-intensity transcranial focused ultrasound stimulation will first be delivered using a range of stimulation parameters during psychophysical and physiological monitoring. A well-tolerated stimulation protocol will be selected for subsequent testing in a blinded randomized sham-controlled trial. The trial will evaluate brain target engagement using magnetic resonance imaging, Food Cravings Questionnaire-State, and changes in subject's weight over the course of the study.

Interventions

DEVICEActive stimulation with Diadem ultrasonic transducer array

Diadem ultrasonic transducer array delivers focused low-intensity ultrasound stimulation

DEVICESham stimulation with Diadem ultrasonic transducer array

Diadem ultrasonic transducer array delivers focused zero-intensity ultrasound stimulation

Sponsors

University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* History of at least one self-reported unsuccessful dietary effort to lose body weight * Body mass index more than or equal to 30 kg/m\^2 or more than or equal to 25 kg/m\^2 with the presence of at least one of the following weight-related comorbidities: hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease.

Exclusion criteria

* Lifetime history of a serious suicide attempt * MRI intolerance or contraindication * Pregnant or breast feeding * Diabetic (HbA1c more than 48 mmol/mol or 6.5%) * A self-reported change in body weight more than 10 lbs within 60 days before screening * Clinically inappropriate for participation in the study as determined by the study team

Design outcomes

Primary

MeasureTime frameDescription
Change in body weight (%) from baseline week 0 to week 16The body weight will be taken prior to each intervention (once per week)The body weight will be quantified with respect to baseline (100%), taken prior to the first intervention.
Number of participants who achieved body weight reduction >= 5%Assessment at week 16Proportion of subjects who have lost at least 5% of their weight at week 16 relative to the baseline week 0.
Food Cravings Questionnaire-StateDuring and immediately after each weekly interventionThis 15-item questionnaire measures immediate level of food craving, each item ranging from 1 (strongly disagree) to 5 (strongly agree). Higher total scores indicate stronger desire to eat.
Hamilton Depression Rating Scale, 17 itemFor up to 16 weeksThis 17-item questionnaire measures the severity of depression. Scores range between 0 (least severe) to 52 (most severe).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026